| Literature DB >> 34420134 |
Yuichiro Yasuda1, Tatsuya Nagano2, Shintaro Izumi3, Mina Yasuda4, Kosuke Tsuruno4, Kazunori Tobino4, Kyosuke Nakata1,5, Kayoko Okamura6, Teruaki Nishiuma7, Kiyonobu Takatsuki8, Yasuhiro Funada9, Hisashi Ohnishi6, Masatsugu Yamamoto1, Yoshihiro Nishimura1, Kazuyuki Kobayashi1.
Abstract
PURPOSE: Sleep-disordered breathing is recognized as a comorbidity in patients with idiopathic pulmonary fibrosis (IPF). Among them, nocturnal hypoxemia has been reported to be associated with poor prognosis and disease progression. We developed a diagnostic algorithm to classify nocturnal desaturation from percutaneous oxygen saturation (SpO2) waveform patterns: sustained pattern, periodic pattern, and intermittent pattern. We then investigated the prevalence of nocturnal desaturation and the association between the waveform patterns of nocturnal desaturation and clinical findings of patients with IPF.Entities:
Keywords: Home sleep apnea test; Idiopathic pulmonary fibrosis; Nocturnal hypoxemia; Percutaneous oxygen saturation
Mesh:
Substances:
Year: 2021 PMID: 34420134 PMCID: PMC9418279 DOI: 10.1007/s11325-021-02456-3
Source DB: PubMed Journal: Sleep Breath ISSN: 1520-9512 Impact factor: 2.655
Fig. 1Examples of waveforms of nocturnal desaturation. Sustained pattern (A), periodic pattern (B), and intermittent pattern (C)
Fig. 2Flow chart of patient recruitment process
Fig. 3Flowchart of nocturnal desaturation pattern judgment
Patients’ characteristics (n = 60)
| Sex | |
| Male/female | 47/13 |
| Age, yr | 72.5 ± 8.6 |
| BMI | 24.1 ± 3.2 |
| Smoking status, | |
| Never/former/current | 16 (26.7)/39 (65)/5 (8.3) |
| Daytime PaO2 (mmHg) | 83.9 ± 11.9 |
| Daytime SpO2 (%) | 96.5 ± 1.4 |
| IPF severity, | |
| I/II/III/IV | 36 (60)/7 (11.7)/12 (20)/5 (8.3) |
| mMRC, | |
| 0/1/2/3/4 | 16 (26.7)/21 (35)/13 (21.7)/10 (16.7)/0 (0) |
| Pulmonary function test | |
| VC, % predicted | 79.5 ± 17.3 |
| FVC, % predicted | 81 ± 17.7 |
| FEV1, % predicted | 84 ± 19.4 |
| DLCO, % predicted | 60.8 ± 16.9 |
| 6MWT | |
| Distance (m) | 372 ± 120 |
| Lowest SpO2 (%) | 90 ± 4.5 |
| KL-6 (U/ml) | 937 ± 673 |
| SP-D (ng/ml) | 223 ± 147 |
| TRPG > 40 mmHg on TTE, n/total | 0/32 |
| Past medical history, n (%) | |
| Hypertension | 28 (46.7) |
| Diabetes mellitus | 19 (31.7) |
| Gastroesophageal reflux disease | 1 (1.6) |
| Ischemic heart disease | 5 (8.3) |
| Chronic obstructive pulmonary disease | 4 (6.7) |
| Lung cancer | 5 (8.3) |
| Depression | 0 (0) |
| Neuromuscular disorder | 0 (0) |
| Medication, | |
| Oral corticosteroids | 3 (5) |
| Sleeping medicine | 2 (3.3) |
| Anti-fibrotic drug | 23 (38.3) |
The data are expressed as the number or mean ± SD
BMI, body mass index, IPF, idiopathic pulmonary fibrosis, VC, vital capacity, FVC, forced vital capacity, FEV1, forced expiratory volume in one second, DLCO: diffusing capacity for carbon monoxide, 6MWT, six-minute walk test, TRPG, transtricuspid pressure gradient, TTE, transthoracic echocardiography
Sleep characteristics
| Total sleep time (min) | 455 ± 90 |
| AHI | 19.3 ± 13.8 |
| Lowest SpO2 (%) | 81.5 ± 6.5 |
| TST90 (%) | 1.3 (0.1–3.1) |
| Classification of nocturnal desaturation, | |
| Sustained | 3 (5) |
| Periodic | 49 (82) |
| Intermittent | 41 (68) |
| Not applicable | 8 (13) |
The data are expressed as the number or mean ± SD or median (interquartile range)
AHI, apnea–hypopnea index, TST90, total sleep time with SpO2 < 90%
Fig. 4Venn diagram of each waveform in patients with idiopathic pulmonary fibrosis